# Pulmatrix, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Pulmatrix, Inc.). ## Overview Pulmatrix, Inc. is a U.S.-based biopharmaceutical company focused on developing inhaled therapeutic products using its patented iSPERSE™ dry powder delivery platform. Its pipeline has included product candidates for respiratory diseases and central nervous system disorders, with development centered on improving how drugs are delivered to the lungs. ## Products & services • iSPERSE™ dry powder inhalation platform • PUR3100 inhaled therapeutic candidate • PUR1900 inhaled itraconazole program • Development of inhaled treatments for COPD and ABPA • Development of inhaled treatments for acute migraine - **iSPERSE™ delivery platform** (0%) — Engineered dry powder technology used to formulate and deliver inhaled drugs. - **Respiratory disease candidates** (60%) — Inhaled product candidates aimed at serious lung diseases such as COPD and ABPA. - **CNS/migraine candidates** (20%) — Inhaled candidates intended for central nervous system disorders such as acute migraine. - **Partnered programs and licensing** (20%) — Programs advanced with collaborators or monetized through licensing and royalties. - iSPERSE™ dry powder inhalation platform - PUR3100 inhaled therapeutic candidate - PUR1900 inhaled itraconazole program - Inhaled treatments for COPD and ABPA - Inhaled treatments for acute migraine ## Customers Pulmatrix does not currently sell approved products; its economic model is centered on partnering with pharmaceutical companies, licensing its technology, and advancing product candidates through development. The main counterparties are potential licensees, development partners, CROs, and CMOs that support clinical and manufacturing work. If products are approved in the future, customers would be patients and healthcare providers in respiratory and migraine treatment markets. - **Pharmaceutical licensing partners** (primary) — Companies that may license iSPERSE or co-develop inhaled candidates to access the platform and pipeline. - **Clinical development vendors** (primary) — CROs and CMOs that perform trials, formulation work, and manufacturing for the pipeline. - **Future patients and prescribers** (secondary) — Patients and clinicians in respiratory and migraine markets who would use approved inhaled therapies. - **Strategic acquirers** (secondary) — Potential buyers of assets or the company seeking to monetize the platform or clinical programs. - Pharmaceutical partners seeking inhaled formulation technology - Licensees that may commercialize iSPERSE-based candidates - CROs and CMOs that support clinical and manufacturing work - Patients with respiratory disease or acute migraine, if approved - Healthcare providers prescribing inhaled specialty therapies ## Geography Pulmatrix is incorporated in Delaware and maintains a mailing address in Framingham, Massachusetts, while operating as a virtual company without owned or leased physical facilities. Its development and partnering activities are tied to the United States, with partnered clinical development and potential commercialization extending outside the U.S. through collaborators such as Cipla. Geography matters because the company depends on cross-border regulatory approvals, partner execution, and access to specialized clinical and manufacturing vendors. - Headquartered in the United States, incorporated in Delaware - Virtual company with no owned or leased physical office space - Framingham, Massachusetts mailing address and operating base - Partnered development outside the United States through collaborators - Future commercialization may depend on U.S. and ex-U.S. approvals ## Strategy Pulmatrix’s strategy is to monetize iSPERSE and its clinical assets through partnerships, licensing, asset sales, or other strategic transactions. The company also seeks to preserve optionality for its inhaled pipeline by advancing candidates only when funding and collaboration support are available. This approach is designed to reduce the capital burden of late-stage drug development while keeping the platform available for external commercialization. - **Monetize the iSPERSE platform** (short-term) — The platform is the core proprietary asset and the main source of potential value creation. - **Preserve development optionality** (medium-term) — Clinical candidates may still have value if funding or partner support becomes available. - **Pursue strategic alternatives** (short-term) — A transaction could provide a path to realize value from the company or its assets. - Monetize iSPERSE through partnerships, licensing, or asset sales - Seek collaborators with commercial and development infrastructure - Advance pipeline programs only when funding is available - Use external CROs and CMOs instead of building large internal ops - Pursue strategic alternatives to maximize value of clinical assets ## Risks Pulmatrix faces the typical risks of an early-stage biopharmaceutical company: clinical failure, regulatory delay, dependence on third parties, and the need for additional capital. Its value is also exposed to transaction execution risk because monetization of the platform or assets depends on successful partnering, asset sales, or other strategic outcomes. - **Clinical development failure** [high] — Product candidates must succeed in testing before they can be commercialized. - **Regulatory approval risk** [high] — The company cannot market products without FDA or foreign approvals. - **Third-party execution risk** [high] — Clinical trials and manufacturing are outsourced to CROs and CMOs. - **Financing risk** [high] — The company expects to need additional capital to continue operations. - **Transaction and monetization risk** [medium] — Value realization depends on successful partnering, merger, or asset sale. - **Cybersecurity and data protection risk** [medium] — Clinical, supplier, and employee data could be disrupted or compromised. - Clinical candidates may fail in preclinical or clinical testing - Regulatory approval may be delayed or never obtained - Third-party CRO and CMO performance can disrupt development - Additional capital may be needed to fund operations - Strategic transactions may not close or may not be favorable ## Accounting Pulmatrix’s accounting is shaped by its development-stage model, where revenue is limited and results depend heavily on collaboration accounting, clinical spend, and estimates around strategic transactions. Investors should watch how the company accounts for collaboration revenue, wind-down activities, and any impairment or disposal accounting tied to asset monetization or merger outcomes. - **Collaboration revenue recognition** — Can create lumpy revenue tied to milestones or wind-down activities - **R&D expense recognition** — Drives operating loss profile and comparability across periods - **Impairment and disposal accounting** — Could materially affect reported results in transaction periods - **Net operating loss carryforwards** — Affects deferred tax asset realizability - Collaboration revenue recognition from partner agreements - Clinical and manufacturing costs expensed as R&D - Potential impairment of intangible or strategic assets - Accounting for merger, asset sale, or dissolution scenarios - NOL carryforwards and valuation allowance considerations --- *Last updated: 2026-04-29T04:50:01.081851+00:00*